title: Hypertrophic obstructive cardiomyopathy in liver transplant patients.
abstract: The optimal treatment strategy for patients with symptomatic hypertrophic obstructive cardiomyopathy (HOCM) and end-stage liver disease (ESLD) is not well defined. Although medical management is the accepted first line treatment, patients who are unresponsive to medication require further interventions. Since ESLD patients have a high operative risk for surgical myomectomy, alcohol septal ablation (ASA) emerges as a good alternative in these cases. The timing of ASA in relation to liver transplantation is still unclear. We report here on the first case of an orthotopic liver transplant-recipient undergoing ASA and the second of a cirrhotic patient requiring ASA as a bridge to liver transplantation. Both patients had a good clinical outcome and we argue that ASA in HOCM patients should be driven by symptom onset, and that in the asymptomatic patient it can be safely deferred until after liver transplantation.
authors.affiliation: University of Alabama at Birmingham, Birmingham, AL, USA.
authors.forename: Fadi G
authors.initials: FG
authors.lastname: Hage
authors.forename: Paco E
authors.initials: PE
authors.lastname: Bravo
authors.forename: Gilbert J
authors.initials: GJ
authors.lastname: Zoghbi
authors.forename: John S
authors.initials: JS
authors.lastname: Bynon
authors.forename: Raed A
authors.initials: RA
authors.lastname: Aqel
mesh_terms: D002312:Cardiomyopathy, Hypertrophic / Q000150:complications* / Q000601:surgery; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods*; D000431:Ethanol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000431:Ethanol